Bolder BioPath Bolder BioPATH, Inc.

  • About Us
  • Services
    • Rheumatoid Arthritis
    • Osteoarthritis
    • Inflammatory Bowel Disease
    • Lupus
    • General Inflammation
    • Pain
    • Cancer
    • Toxicology and Pharmacokinetic Studies
    • Ex Vivo Services
    • Pathology
    • Anemia
    • Model Development
  • Publications
  • Request a Quote
  • Contact
  • G5-AN-1-400X
  • AAALAC-Acc.
  • Gp-2-An-10-Colon-D3-100x
  • Gr-2-AN-2-630X
  • Gr-2-AN-7-L-16X
  • Grp-2-An-8-Kidney-100x
  • Grp-3c-An-14-Prox-Colon-1-100x
  • Grp-8-An-67-Cord-3-100x
  • Grp5c-An14-Level1-50x
  • Grp7-An7-R-Knee-ED1-100x
  • Grp10-An6-Forepaw1-16x
  • GrpA-An8-Kidney-100x

Welcome to Bolder BioPATH

Bolder BioPATH, Inc. is a preclinical CRO specializing in In Vivo models of Rheumatoid Arthritis, Osteoarthritis, Inflammatory Bowel Disease as well as other autoimmune and inflammation models, Our goals are to provide preclinical (efficacy and toxicity) data to support advancing proteins and small molecules to IND/NDA stage.

Tell Us About Your Project! Get a Quote »

Contact Us

  • This field is for validation purposes and should be left unchanged.

Recent Posts

  • A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

    05-02-17

    Come hear Leo Fitzpatrick discuss the paper, A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice, this Saturday May 6, from 10:30am-10:45am in Room S102d at McCormick Place, California NorthState University College of Pharmacy. Authors: Leo Fitzpatrick, Robert O’Connell, George Talbott, Phillip Bendele, Gordon Alton, Jim Zapf

    AAALAC Accreditation

    03-14-17

    Bolder BioPATH now has FULL accreditation through AAALAC International, effective as of March 9, 2017.

  • OARSI 2017 World Congress on Osteoarthritis

    01-24-17

    Come meet Bolder BioPATH at the OARSI 2017 World Congress on Osteoarthritis in Las Vegas from April 27 to 30! We’ll be set up in booth #8.

    Digestive Disease Week Conference, May 6-9

    12-22-16

    Come meet Bolder BioPATH at the DDW Conference in Chicago from May 6 to 9! We’ll be set up in booth #1712.

  • Important Things to Know About Intra-Articular Testing of Drugs in Animals – ACT’s 37th Annual Meeting

    08-25-16

    Important Things to Know About Intra-Articular Testing of Drugs in Animals Alison M. Bendele DVM, PhD, DACVP Bolder BioPATH, Inc, Boulder, CO  Monday Nov. 7th – Symposium 7 , 3:50 PM–4.20 PM    Intra-articular (IA) administration of drugs offers an opportunity to directly target joints (primarily osteoarthritic) for anabolic, antidegenerative, analgesic, lubricant, anti-inflammatory and other potential […]

    Now offering FACS analysis through Clinimmune Labs.

    08-23-16

    Bolder BioPATH has started offering FACS analysis on some of our models with help from the folks at Clinimmune Labs in Denver.

  • 19th IRA International Conference – 2016

    07-22-16

    Come by Bolder BioPATH’s booth at the 19th IRA International Conference in San Diego.  We hope to see you there!

    Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership

    04-26-16

    Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).

Website designed by Studio98

  • In Vivo efficacy models
  • Ex Vivo Services
  • Pathology
  • Terms of Service
  • Privacy Policy

©2015 Bolder BioPATH, INC. All rights reserved.Privacy Policy